Aurobindo Pharma Limited announced that the United States Food and Drug Administration (US FDA) completed a routine inspection at its subsidiary, AuroPeptides Ltd. The inspection, conducted from August 17-21, 2026, resulted in a single observation related to facility and equipment maintenance. This observation does not concern data integrity or GMP compliance. Corrective actions were initiated during the inspection, with a formal response to be submitted timely.
US FDA Inspection Update
Aurobindo Pharma Limited has announced the conclusion of a routine inspection by the United States Food and Drug Administration (US FDA) at its subsidiary, AuroPeptides Ltd. The facility, located in Telangana, is a manufacturer of Peptide APIs.
Inspection Details and Outcome
The inspection took place from August 17 to August 21, 2026. Aurobindo Pharma is pleased to report that the inspection concluded with only one (1) observation. This observation pertains specifically to the maintenance of the facility and equipment. Importantly, it does not relate to data integrity or Good Manufacturing Practice (GMP) compliance.
Corrective Actions and Commitment
Corrective actions to address the observation were already initiated during the course of the inspection. The company will submit its formal response within the stipulated timeline. This outcome underscores Aurobindo Pharma’s ongoing dedication to maintaining high standards of quality and compliance across all its manufacturing sites.
The company commits to keeping the stock exchanges informed of any further developments as required by applicable regulations.
Source: BSE
